A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Item

http://www.wikidata.org/entity/Q36799192

Q36799192

about

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.Current Treatment of Chronic Lymphocytic Leukemia.Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells.Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.Flow cytometric single cell analysis reveals heterogeneity between adipose depots.Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies

P2860

Q37267608-5F7DC259-1D37-49C6-B58B-18D256A6503F Q37429218-5A3220CC-2BEB-4790-BD93-F6571394916A Q38672646-3DF91755-E3A1-4E23-A621-A24A3F70770E Q38962267-E1CCBC48-46F5-4378-B102-037E1CAB6319 Q39129372-F09D7052-8845-43D2-A0C4-55333FE8D6E9 Q39214379-5EDEF134-C790-4F95-A8D6-2D7B68F591BC Q39266366-29E739D7-C363-431C-B6E3-4918D7C6A661 Q39329093-2C81FBCC-7EDB-4006-9E4E-3E5830B4EF2A Q41147408-1B57A11D-CC87-49D8-9F8E-C88EE81422C5 Q41320162-E1F29963-DCF6-4D2D-A742-2DFCC04B6C87 Q42318090-B255A514-41E8-45B8-9F77-CCAD40489CBE Q42378526-9B2C725B-D2D9-4058-993F-0EC4F78268F6 Q48198290-7500DB89-4A30-4919-A648-6631BF0B0371 Q48268599-CBA17040-61E6-4CB0-AC91-C27CE15717A3 Q48367614-CDB77B2C-5045-4DD3-9C7C-B8BF47CD8FFC Q49641900-E5E3D3AC-2F8B-4C45-A360-2C5E5908DAF1 Q49818588-EDAA31A7-F385-43A8-9973-148924720AFC Q50209046-26952AE4-844E-4105-8AFA-F85A378DC80D Q52770382-BE8FD669-8340-4E52-BA12-B0864A881B9D Q58723303-79464D0F-C43C-4985-9D6A-62A2547EE6C1

P2860

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Item

http://www.wikidata.org/entity/Q36799192

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A complementary role of multip ...... earch Initiative on CLL study.

@en

type

Item

label

A complementary role of multip ...... earch Initiative on CLL study.

@en

prefLabel

A complementary role of multip ...... earch Initiative on CLL study.

@en

P1476

A complementary role of multip ...... search Initiative on CLL study

@en

P2093

A Agathangelidis

http://www.w3.org/2001/XMLSchema#string

A P Kater

http://www.w3.org/2001/XMLSchema#string

A Pettitt

http://www.w3.org/2001/XMLSchema#string

A Soosapilla

http://www.w3.org/2001/XMLSchema#string

C Fazi

http://www.w3.org/2001/XMLSchema#string

C Hanson

http://www.w3.org/2001/XMLSchema#string

C M Sanders

http://www.w3.org/2001/XMLSchema#string

C Moreno

http://www.w3.org/2001/XMLSchema#string

C Yuan

http://www.w3.org/2001/XMLSchema#string

D O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

IMGT-ONTOLOGY for immunogenetics and immunoinformatics.

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

P2888

leu.2015.313

P304

929-936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2015.313

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286220418

http://www.w3.org/2001/XMLSchema#string

P698

26639181

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

4832072

http://www.w3.org/2001/XMLSchema#string

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

about

P2860

P2860

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932